Price Chart

Profile

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
URL https://www.vikingtherapeutics.com
Investor Relations URL http://ir.vikingtherapeutics.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Apr. 26, 2024 (est.)
Last Earnings Release Feb. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
URL https://www.vikingtherapeutics.com
Investor Relations URL http://ir.vikingtherapeutics.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Apr. 26, 2024 (est.)
Last Earnings Release Feb. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A